RNA-Seq from PMM2-CDG Patients and Healthy Controls
Biomarkers (3)
- ANALYTE_TYPE - Analyte Type (phv00530170.v1.p1)
- RATIO_260/230 - Ratio of the absorbances at 260nm and 230nm (phv00530175.v1.p1)
- RATIO_260/280 - Ratio of the absorbances at 260nm and 280nm (phv00530174.v1.p1)
Demographics (1)
- SEX - Biological sex (phv00530163.v1.p1)
Other (16)
- BODY_SITE - Body site where sample was collected (phv00530169.v1.p1)
- CELL_TYPE - Type of cell from which the sample was obtained (phv00530172.v1.p1)
- CONDITION - Condition of the sample (phv00530176.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00530162.v1.p1)
- DOSE - Dose of the treatment (phv00530180.v1.p1)
- IS_TUMOR - Tumor status (phv00530171.v1.p1)
- RNA_EXTRACTION - Method used for RNA extraction (phv00530173.v1.p1)
- SAMPLE_ID - Sample ID (phv00530168.v1.p1)
- SAMPLE_ID - Sample ID (phv00530167.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00530165.v1.p1)
- STUDY_INC_TEMP - Temperature in which the sample was subjected to the treatment (phv00530179.v1.p1)
- STUDY_INC_TIME - Duration that the sample was subjected to the treatment (phv00530178.v1.p1)
- STUDY_TMNT - Treatment to which the sample was subjected (phv00530177.v1.p1)
- SUBJECT_ID - Subject ID (phv00530161.v1.p1)
- SUBJECT_ID - Subject ID (phv00530166.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00530164.v1.p1)